| Neuroendocrine Neoplasm altered in cohorts of …ALTERED_INderived146 of 146show fewer |
|---|
| ← altered in cohorts of | POLE 20 / 20 cases (100 %) · ssm · sclc_cancercell_gardner_2017 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TP53 103 / 120 cases (86 %) · ssm · sclc_ucologne_2015 · largest of 4 cohorts | — | — | Lung Small Cell Carcinoma | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RB1 87 / 120 cases (73 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | AMY1A 128 / 179 cases (72 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AMY1B 128 / 179 cases (72 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AMY2A 128 / 179 cases (72 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AHCYL1 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALX3 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AMPD2 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AMY1C 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AMY2B 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLCA1 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLCA2 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLCA4 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COL24A1 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CSF1 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EPS8L3 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FNDC7 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GNAI3 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GNAT2 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPR61 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GSTM1 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GSTM2 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GSTM3 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GSTM4 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GSTM5 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HS2ST1 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNC4 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LMO4 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ODF2L 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLPPR4 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RBM15 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SELENOF 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH3GLB1 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC16A4 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC6A17 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | STRIP1 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | STXBP3 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TGFBR3 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBL4B 127 / 179 cases (71 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ABCA4 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ABCD3 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AKNAD1 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AMIGO1 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGAP29 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATXN7L2 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BARHL2 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BCAR3 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BCL10 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BRDT 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BTBD8 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf146 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf194 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC18 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCN1 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CD53 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CELSR2 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CEPT1 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHI3L2 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CHIA 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLCC1 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CYB561D1 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DDAH1 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DENND2D 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DIPK1A 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DNTTIP2 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DR1 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DRAM2 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ELAPOR1 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EPHX4 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EVI5 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FNBP1L 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GBP6 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GCLM 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GFI1 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GLMN 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPSM2 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HIPK1 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNA10 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNA2 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNA3 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LAMTOR5 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRIF1 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MTF2 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYBPHL 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OLFM3 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLPPR5 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PROK1 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRPF38B 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSMA5 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PSRC1 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RNPC3 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPAP2 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL5 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SNX7 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SORT1 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SYDE2 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMED5 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM167B 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VCAM1 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WDR47 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNHIT6 126 / 179 cases (70 %) · ssm · TCGA-PCPG | — | — | Paraganglioma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TTN 77 / 120 cases (64 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RYR2 54 / 120 cases (45 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | LRP1B 51 / 120 cases (43 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MUC16 49 / 120 cases (41 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ZFHX4 46 / 120 cases (38 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MEN1 36 / 98 cases (37 %) · ssm · panet_arcnet_2017 · largest of 2 cohorts | — | — | Pancreatic Neuroendocrine Tumor | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | USH2A 44 / 120 cases (37 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CSMD3 42 / 120 cases (35 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | NAV3 35 / 120 cases (29 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PCDH15 32 / 120 cases (27 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | COL11A1 31 / 120 cases (26 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CSMD1 28 / 120 cases (23 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | EYS 27 / 120 cases (23 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MUC17 27 / 120 cases (23 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SYNE1 27 / 120 cases (23 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | DAXX 22 / 98 cases (22 %) · ssm · panet_arcnet_2017 · largest of 2 cohorts | — | — | Pancreatic Neuroendocrine Tumor | 2 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ATRX 21 / 96 cases (22 %) · ssm · panet_msk_2018 | — | — | Pancreatic Neuroendocrine Tumor | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ANKRD30B 26 / 120 cases (22 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FAM135B 26 / 120 cases (22 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FSIP2 25 / 120 cases (21 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TMEM132D 25 / 120 cases (21 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ERICH3 24 / 120 cases (20 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PKHD1 24 / 120 cases (20 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SI 24 / 120 cases (20 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PKHD1L1 23 / 120 cases (19 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RYR1 23 / 120 cases (19 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SPTA1 23 / 120 cases (19 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TENM1 23 / 120 cases (19 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | XIRP2 23 / 120 cases (19 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ADGB 22 / 120 cases (18 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FAT3 22 / 120 cases (18 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KMT2D 22 / 120 cases (18 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | NCAM2 22 / 120 cases (18 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RYR3 22 / 120 cases (18 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TNR 22 / 120 cases (18 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | DMD 21 / 120 cases (18 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | HCN1 21 / 120 cases (18 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PCLO 21 / 120 cases (18 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | COL22A1 20 / 120 cases (17 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CSMD2 20 / 120 cases (17 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | DNAH5 20 / 120 cases (17 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FMN2 20 / 120 cases (17 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SPHKAP 20 / 120 cases (17 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ZNF729 20 / 120 cases (17 %) · ssm · sclc_ucologne_2015 | — | — | Lung Small Cell Carcinoma | 1 | Observed | cbioportal | graph → |